Repligen
RGEN
#2470
Rank
$7.44 B
Marketcap
$132.02
Share price
-1.15%
Change (1 day)
11.08%
Change (1 year)
Categories

Repligen (RGEN) - Total liabilities

Total liabilities on the balance sheet as of March 2026 : $0.82 Billion USD

According to Repligen 's latest financial reports the company's total liabilities are $0.82 Billion USD. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Repligen - Total liabilities on balance sheet (from 2001 to 2026)

Total liabilities by year

Year Total liabilities Change
2025-12-31$0.84 B-1.56%
2024-12-31$0.85 B-1.08%
2023-12-31$0.86 B39.53%
2022-12-31$0.62 B2.07%
2021-12-31$0.60 B62.76%
2020-12-31$0.37 B9.81%
2019-12-31$0.34 B113.98%
2018-12-31$0.15 B4.66%
2017-12-31$0.15 B26.49%
2016-12-31$0.12 B411.51%
2015-12-31$23.48 M41.83%
2014-12-31$16.56 M12.21%
2013-12-31$14.75 M14.54%
2012-12-31$12.88 M
2011-03-31$5.2 M-1.74%
2010-03-31$5.29 M14.43%
2009-03-31$4.63 M-2.15%
2008-03-31$4.73 M33.79%
2007-03-31$3.53 M11.73%
2006-03-31$3.16 M-4.56%
2005-03-31$3.31 M35.36%
2004-03-31$2.45 M9.25%
2003-03-31$2.24 M-15.88%
2002-03-31$2.66 M112.18%
2001-03-31$1.25 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Pfizer
PFE
$117.21 B 14,102.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
$61.22 B 7,317.83%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
$110.14 B 13,246.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
$66.37 B 7,942.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
$82.4 M-90.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
$1.18 B 43.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
$1.49 B 81.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
$0.46 B-43.62%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
$2.37 B 188.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
$4.74 B 474.57%๐Ÿ‡บ๐Ÿ‡ธ USA